Vertaling van "new technologies " (Frans → Nederlands) :

TERMINOLOGIE

virus Epizootic hemorrhagic disease, New Jersey
epizootisch hemorrhagische ziekte, New Jersey-virus

virus New Minto
New Minto-virus

New York
New York

IN-CONTEXT TRANSLATIONS

Lire le rapport complet en anglais: Green jobs and occupational safety and health: Foresight on new and emerging risks associated with new technologies by 2020 (PDF)
Lees het volledige rapport in het Engels: Green jobs and occupational safety and health: Foresight on new and emerging risks associated with new technologies by 2020 (PDF)

‘How can new Media and new Technologies improve the dissemination of OSH knowledge and how to measure relevance and impact?’ FR Paris, 18/09/2013
‘How can new Media and new Technologies improve the dissemination of OSH knowledge and how to measure relevance and impact?’ FR Paris, 18-09-2013

- Klein HG, Anderson D, Bernardi MJ, Cable R, Carey W, Hoch JS, et al. Pathogen inactivation: making decisions about new technologies.
- Klein HG, Anderson D, Bernardi MJ, et al. Pathogen inactivation: making decisions about new technologies.

European Group on Ethics in Science and New Technologies; [http ...]
European Group on Ethics in Science and New Technologies; [http ...]

Escarce JJ., 1996, " Externalities in hospitals and physician adoption of a new surgical technology: An exploratory analysis" , Journal of Health Economics, Vol. 15(6), pp 715-734.
Escarce JJ., 1996, ‘Externalities in hospitals and physician adoption of a new surgical technology: An exploratory analysis’, Journal of Health Economics, Vol. 15(6), pp. 715-734.

Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.
This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.

Suite à une question parlementaire (n°K533 du 22/08/05) et aux diverses questions émanant des hôpitaux à l’attention de l’administration et des organismes de recherche tels que le VITO (Vlaamse Instelling voor Technologisch Onderzoek), le nouveau groupe de travail « New Communication Technologies », qui s’occupe actuellement des radiations non ionisantes, émet dès lors de sa propre initiative, des recommandations au sujet de l’utilisation des systèmes de communication sans fil et des GSM dans les hôpitaux.
Naar aanleiding van een parlementaire vraag (nr. K533 op 22/08/05) en diverse vragen vanuit ziekenhuizen aan de administratie en onderzoeksinstellingen zoals het VITO (Vlaamse Instelling voor Technologisch Onderzoek), brengt de nieuwe werkgroep “New Communication Technologies”, die nu de niet-ioniserende straling behandelt, dan ook, op eigen initiatief, aanbevelingen uit omtrent het gebruik van draadloze communicatiesystemen en GSM in ziekenhuizen.